- Research
- Medical & Pharmacological
- Genetic & Metabolic Screening
What genetic testing can — and can't — tell you about autism
A well-established diagnostic tool that finds a cause for some families — but it's a test, not a treatment, and most results come back negative or uncertain.
Podcast·Two-voice deep dive
Listen to the discussion
Chapters & transcript
This is an AI-generated discussion of this article, transcribed automatically. The written summary below is the reviewed source — if the two differ, go by the summary.
0:00What is this discussion about?
Host A Imagine finally discovering the exact underlying genetic reason for your child's autism, like finally getting an answer to this massive question you've been asking for years. Right. But then, you know, you realize that uncovering that specific piece of DNA might legally allow an insurance company to completely deny your child life insurance when they become an adult.
Host B Yeah, it's a terrifying thought.
Host A It really is.
Host B Yeah.
Host A So today, you and I are taking a deep dive into the double-edged sword of genetic testing. We've got this fascinating stack of internal audit and summary documents straight from Spectrum Connect.
Host B We do.
Host A And our mission today is to explore genetic and metabolic testing. So things like chromosomal microarrays and exome sequencing, specifically for children who are diagnosed with or being evaluated for autism.
Host B And, you know, right out of the gate, we really need to establish the absolute core core baseline from these sources.
Host A Yeah, set the stage for us.
Host B So everything we're going to discuss today rests on this one fundamental distinction, which is that autism is a clinical and behavioral diagnosis. Genetic testing, on the other hand, is a medical diagnostic tool. So when a doctor does like a cheek swab or a blood draw, they are looking for an underlying structural or molecular cause in a child's DNA.
Host A OK, but it's not a treatment.
Host B Exactly. And that is the critical piece here. Genetic testing is not a treatment. It's not going to improve or alter a child's autism symptoms in any way. It's purely an informational diagnostic tool.
Host A I feel like it's essentially like, well, like plugging one of those diagnostic scanners into your car when the check engine light comes on.
Host B Oh, that's a great way to put it.
Host A Right. Because you plug the scanner in under the dashboard and it reads the code. It tells you exactly why the light is flashing. Maybe it's a faulty oxygen sensor.
Host B Yeah.
Host A But just plugging in the scanner and reading the code doesn't actually fix the engine. It just points the mechanic in the right direction. Like it gives you the why, but it does absolutely nothing to execute the actual repair.
Host B That is a brilliant analogy. You aren't changing the engine. You're just trying to figure out if there was a manufacturing quirk at the factory level.
Host A Right.
Host B And you aren't changing the child's behavioral or clinical reality either. You're just looking at their foundational biological blueprint to see if there is a known genetic explanation for that reality.
2:23Why test at all if it doesn't treat the autism?
Host A Which honestly brings up a really obvious tension. How so? Well, if this test doesn't treat the autism and it doesn't change the immediate behavioral reality for the kid, why do major medical guidelines like the American College of Medical Genetics and Genomics heavily recommend putting a child through it?
Host B That's the big question. Right.
Host A So that tells me we need to look at what these tests are actually scanning for and how often they actually find something.
Host B Yeah. Let's get into the numbers.
2:49What's the first genetic test kids usually get?
Host A So if a parent agrees to this, what's the actual first step? Like, are we running a massive billion dollar full genome sequence right out of the gate?
Host B Usually, no. The historical first-line test is something called a chromosomal microarray, or a CMA.
Host A Okay, and what does that actually look for?
Host B Well, to use your car manual analogy, or I guess if the genome is a giant instruction manual, a microarray isn't looking for single spelling mistakes.
Host A Oh, it's broader than that.
Host B Much broader. It's scanning the book to see if entire pages or even whole chapters have been accidentally ripped out or duplicated. It looks for extra or missing pieces of chromosomes.
Host A Wow, okay. And how often does it actually find a missing chapter like that?
Host B The diagnostic yield for a microarray is about 1 in 10 children.
Host A Okay, so 10%.
Host B Yeah, the sources cite roughly 5% to 10% for idiopathic autism, which just means autism without an already obvious known cause. Got it. Though one specific cohort highlighted in the documents from PubMed Central found a 15.2% pathogenic result rate.
Host A So it's definitely helpful, but you're still talking about a vast majority of patients going through this test and walking away without a clear genetic answer.
Host B Exactly. Most walk away with nothing concrete.
4:02What happens when the first test comes back normal?
Host A Okay, so if the microarray is scanning for missing chapters, what happens when all the chapters are physically there, but the child still clearly has autism? Do we then start looking for the spelling mistakes?
Host B We do. That's exactly where we move to whole exome sequencing, or WES.
Host A WES, okay. Yeah.
Host B And the exome makes up a tiny fraction of your entire genome, about 1% to 2%. But it contains all the protein-coding genes.
Host A The ones that actually do the heavy lifting.
Host B Right. These are the genes that actually build the body and the brain. Exome sequencing reads the actual letters of those specific genes, looking for tiny, tiny typos.
Host A And what's the yield on that?
Host B According to the Srivastava 2019 consensus statement in our sources, exome sequencing has about double the yield of a microarray, so roughly 16%.
Host A 16%. Does that number change based on the child's specific presentation, like depending on their symptoms?
Host B It changes drastically. If the child has a co-occurring intellectual disability alongside their autism, that exome sequencing yield jumps all the way up to 30 to 37 percent.
Host A Wait, really? Almost 40 percent?
Host B Yeah, it's a huge jump.
Host A What about Fragile X? Because, you know, when you hear people talk about autism and genetics, Fragile X is usually the first name dropped. Is that something the exome test picks up?
Host B So fragile X syndrome is caused by a very specific mutation in the FMR1 gene. But here's the fascinating nuance in the clinical data. If you just test universally for fragile X, meaning you test every single child evaluated for autism without looking for any specific family history or physical clinical features pointing to it,
Host A Like just blanket testing everyone.
Host B Exactly. The diagnostic yield for that is incredibly low. It's only about 1%, usually between 0.5 and 2%.
Host A Why is the yield so incredibly low if it's so famous for being linked to autism?
Host B Because Fragile X usually presents with very specific physical and developmental markers, things like particular facial features or joint hypermobility.
Host A Oh, I see.
Host B So if you just test blindly without looking for those clinical signs first, you're essentially looking for a needle in the wrong haystack.
Host A That makes sense.
Host B Because of that low yield, there's a massive debate in the clinical community over whether Fragile X should automatically be considered a first-tier test for every child or if it should be strictly reserved for those who actually show the specific signs.
Host A I want to pause on where these numbers are coming from, actually. You mentioned the Srivastava consensus and the PubMed cohorts. I imagine in a field this lucrative, there are a lot of companies trying to inflate their success rates.
Host B You hit the nail on the head. This is a crucial note on data provenance in the audit. Okay. The internal documents explicitly flag a commercial testing lab called Genidex. In their marketing materials, they promote the absolute highest possible EXIM yields.
Host A Oh, yeah, because the commercial labs have a financial incentive to make you think their test finds the answer every single time.
Host B Precisely. They might use a highly curated cohort of patients who were like already highly suspected of having a genetic condition, which artificially inflates the success rate of the test.
Host A Right. Stacking the deck.
Host B Exactly. So the commercial figures are treated as strictly promotional by the audit, while the peer reviewed cohorts anchor the realistic real world ranges we're discussing today.
Host A Good to know. But I have to challenge the testing sequence, though.
Host B Sure. Go ahead.
Host A If exome sequencing reads the spelling mistakes and gives you a 16 to 37% yield, literally double what a microarray gives you, why wouldn't every single doctor just skip the microarray and start with the exome test immediately? Are we forcing families through unnecessary, time-consuming hoops?
Host B It's a highly debated question right now, actually. Historically, microarrays were just cheaper and easier to interpret, so they became the default first step.
Host A Okay. Cost makes sense.
Host B But as XM sequencing gets cheaper, guidelines are slowly shifting. However, to truly understand why doctors order what they do, we have to look past the raw percentages of yield. We have to examine the real world stakes, because what is a 16% chance of finding an answer actually by a family?
Host A Right. Moving from did we find something to what on earth do we actually do with this information?
Host B Exactly, which is known as clinical utility.
8:22What actual medical benefit does a positive result give a family?
Host B The clinical utility of a positive pathogenic result is immense.
Host A Even if it's only found in a minority of kids.
Host B Yes. It only helps the minority who actually test positive. But for that minority, the impact alters the entire trajectory of their medical care.
Host A Wow.
Host B Okay. A 2022 clinical management review in the journal Genes found that 72% of patients who get a positive genetic result end up with added medical recommendations.
Host A Okay. What does that look like in practice, though? Give me an example of an added medical recommendation.
Host B Well, one cohort study showed that 26% of positive results triggered 25 extra targeted exams.
Host A Oh, wow.
Host B We're talking about critical medical surveillance. Some genetic variants linked to autism are also linked to a highly increased risk of seizures or specific structural heart defects or metabolic crashes.
Host A So it's not just about the autism.
Host B Not at all. A positive result gives the pediatrician a map. It tells them to look for those specific physical dangers before they become life-threatening emergencies.
Host A That is huge.
Host B It gets the family referred to the right specialists immediately, and it helps them avoid harmful interventions that just wouldn't work for their child's specific biology. That makes total sense. Think of it like finally discovering the specific species of a houseplant you've been struggling to keep alive for months.
Host A Right, exactly.
Host B Because finding out the scientific name of the plant doesn't physically alter the leaves, obviously.
Host A Yeah.
Host B But suddenly you can look it up and you know exactly how much water it needs, what kind of soil pH it requires, and whether it needs direct sunlight or shade to actually thrive.
Host A That is a perfect extension of the concept. You're handing the family the instruction manual for the soil and the sunlight.
Host B Yeah.
Host A But it's also about preventing you from pouring the wrong fertilizer on it. Some kids might be put on certain medications for their behaviors that their specific genetic profile actually metabolizes really poorly.
Host B Oh, so it prevents bad reactions.
Host A Exactly. Knowing the genetics stops that trial and error process. And beyond immediate medical care, these results have immense value for family planning.
Host B You mean like understanding the likelihood of a second child having the same diagnosis? Right. It's called recurrence risk. Without a genetic test, a doctor can only give a family a vague general population estimate for having another child with autism.
Host A Which isn't super helpful.
Host B No, it's not. But if you find a specific genetic cause, a counselor can tell the family the exact statistical odds, whether it's like a 1% random mutation chance or a 25 to 50% inherited chance.
Host A That's incredibly concrete.
Host B It is. Plus, having a highly specific genetic diagnosis allows a family to find incredibly niche support communities.
Host A Oh, that's a good point.
Host B Yeah. They aren't just navigating the broad autism community anymore. They can find a Facebook group of 400 families across the entire world who share that exact same rare gene variant.
Host A People who truly understand their daily reality.
Host B Exactly.
Host A You know, it's incredibly easy to advocate for genetic testing when we talk about it like this. The added surveillance, the tight-knit community, the clear family planning, it all sounds incredibly empowering.
Host B It does.
Host A But if there's a 16% chance of a clear answer, that leaves a massive 84% who don't get that clean resolution. And the sources highlight a very messy reality here, don't they?
11:46What is a 'variant of uncertain significance'?
Host B They really do. And this is where we have to introduce the most stressful acronym in genetics, which is the VUS.
Host A The VUS. Let me guess. This is the gray area.
Host B It is the ultimate gray area. It stands for variant of uncertain significance.
Host A Okay. Meaning what exactly?
Host B A VUS means the test did its job. It found a genetic change, a typo in the child's DNA that is not typical. But science simply doesn't know what that typo means yet.
Host A Oh, man.
Host B There isn't enough data in the global genetic databases to say if this specific typo causes the autism or if it's just a completely harmless quirk of human variation, like having a slightly different shaped earlobe.
Host A Right.
Host B And the worst part is these uncertain variants frequently outnumber the clear diagnoses.
Host A Really? What are the actual numbers on that? How common is a VUS?
Host B So remember that microarray cohort we mentioned earlier, the one that found a 15.2% pathogenic rate?
Host A Yeah, I remember.
Host B Well, that exact same study found a 27.1% VUS rate.
Host A Oh, my God.
Host B Yeah. So a family is nearly twice as likely to walk away with a giant stressful question mark as they are to get a solid, actionable answer.
Host A That has to totally skew the statistics. If a lab says, hey, we found variants in 40% of our patients, they might be burying the fact that the majority of those variants are completely meaningless right now.
Host B The documents refer to that exactly as apparent yield inflation.
Host A Apparent yield inflation, yeah.
Host B But the real harm channel here isn't statistical. It is entirely psychosocial for the parents. You're handing an already exhausted parent a medical document that says, your child's DNA is mutated, but we have absolutely no idea if it matters.
Host A It provides zero actionable medical answers, but a massive amount of anxiety. And the VUS isn't the only unexpected thing these tests can find, is it?
13:33What are 'secondary findings', and why are they controversial?
Host A We have to talk about secondary findings.
Host B Yes. When you do broad testing, like whole exome sequencing, the machine reads everything. You are casting a massive net. The American College of Medical Genetics actually maintains a list of about 80 secondary finding genes.
Host A What are those?
Host B These are genes linked to severe actionable health risks, like a high risk for sudden cardiac death or certain types of highly aggressive cancers.
Host A Oh, wow.
Host B And they have absolutely nothing to do with autism.
Host A Okay. I have to challenge this premise entirely. Go for it. We are told constantly in health care that more data is better. But handing a parent who is just trying to figure out an autism diagnosis, a paper that says their three-year-old child, and by extension, the parent who passed it down, has a gene for a rare aggressive cancer.
Host B Yeah.
Host A I mean, that completely shatters the idea that more data is always good. That feels like an unbearable emotional burden disguised as a medical service.
Host B It is a profound dilemma, and it's exactly why the sources frame this testing as carrying a very high informational risk.
Host A Informational risk.
Host B The physical risk of a cheek swab or a blood draw is practically zero, but the informational risk is staggering. You cannot unknow this information once a lab gives it to you.
Host A And the burdens aren't just psychological either. A cancer gene or a cardiac gene on a medical record has massive ripple effects.
Host B It really does.
14:54Can a genetic test result be used against your child later?
Host A Which leads us directly into what might be the most shocking part of these documents, which is the legal and financial minefield.
Host B Yeah, this falls under the umbrella of ELSI and the audit ethical, legal, and social implications. And it's detailed heavily in a source from the Helen Journal. Let's look at the realities of genetic privacy and insurance access.
Host A Most people assume that in the United States their medical data is totally protected. We assume we cannot be discriminated against because of a genetic test.
Host B And you are partially right, thanks to a 2008 law called GINA, the Genetic Information Non-Discrimination Act. GINA protects families from discrimination regarding health insurance and employment. A health insurer cannot legally deny you coverage or hide up your premiums just because a genetic test showed a risk for cancer or heart disease.
Host A OK, but what did they leave out? Because the sources outline a massive loophole here.
Host B The GINA loophole is vast. The law explicitly does not cover life insurance, disability insurance, or long-term care insurance.
Host A Wait, what? I want you to just process the gravity of that for a second. Think about a child 25 years from now. They are an adult, they're managing their autism well, they want to buy a house, and their mortgage lender requires a life insurance policy. Right. A life insurance underwriter can legally look at a genetic test that the person took when they were three years old, see a secondary finding or pathogenic variant, and deny them coverage entirely.
Host B Completely legally. Yeah. Or they might charge them absolutely astronomical premiums. Life insurance is fundamentally about risk pooling based on mortality, so they are legally allowed to use that genetic data.
Host A That is insane.
Host B Parents are caught in this incredible squeeze. They take a test today because a doctor says it might help manage their toddler's immediate developmental needs, only to accidentally price that same child out of disability or life insurance decades later.
Host A And that's assuming they can even get the test in the first place.
Host B Right. The testing itself is walled off by extreme access and equity. Over 50 percent of health insurance denials for the actual genetic testing. cite the tests as not medically essential or experimental.
Host A So families are fighting tooth and nail with their health insurance just to get the swab paid for, while simultaneously risking their child's future ability to get life coverage. Exactly. With all these layers stacked up, the microarrays looking for missing chapters, the exomes finding the spelling mistakes, the VUS gray areas, the massive insurance loopholes, Where does this leave parents who are just trying to do the right thing for their kids?
Host B It leaves them needing intense professional guidance.
17:33What are the key takeaways?
Host B If we synthesize the main takeaways from all these sources, the conclusion is pretty clear.
Host A Which is?
Host B Genetic testing for autism offers a real chance at profound understanding. That 16% to 37% chance of finding a cause can drastically alter medical management for the better. But it carries extremely high informational and financial risks.
Host A Which means you shouldn't just agree to a swab in a 15-minute pediatrician visit.
Host B Exactly. This is why the sources stress repeatedly the absolute necessity of consulting a genetic counselor before the test is ordered, not just after the confusing results come back.
Host A That makes a lot of sense.
Host B A counselor helps the family plan for the possibility of a negative result, a life-changing pathogenic result, or a highly stressful VUS. and they help them understand how they will react to each scenario legally and emotionally. Ultimately, genetic testing is a tool to understand the child's biology. It is not a tool to change who they are.
Host A It's about getting the instruction manual for the soil and the sunlight.
Host B Beautifully said.
Host A And this is exactly why families need clinical guidance to navigate these gray areas. And actually, that's a perfect time to mention something specific from our sources today. Currently, Spectrum Connect is bridging the science of autism therapies to make it more approachable for parents. If you are a credentialed expert, an MD, PhD, PsyD, or DO, and would like to help us in validating our findings, email us at research at spectrumconnect.us.
Host B Bringing more clinical expertise to bear on these incredibly nuanced questions is exactly what will better equip families to navigate these choices.
Host A Exactly. Now, to close us out, I want to leave you with a lingering question to think about based on everything we explored today. We talked heavily about the variant of uncertain significance, that stressful gray area where science doesn't know what a typo means yet. Right. But science doesn't stand still. Genetic databases are rapidly expanding every single day as millions of people get sequenced.
Host B They are.
Host A So will today's incredibly stressful variant of uncertain significance automatically become tomorrow's clear diagnosis? And if so, how in the world will our fragmented health care systems manage to track down and update families 5, 10, or 20 years later when science finally figures out what their child's gray area result actually meant?
Host B It's a huge logistical nightmare.
Host A Right. If you plug the diagnostic scanner into your car a decade ago and got a blank code, who is going to proactively call you today to tell you what's actually wrong with the engine? It's something to think about. Until next time, keep exploring.
Key Takeaways
It's a well-established diagnostic tool — testing finds an underlying genetic cause in roughly 1 in 8 to 1 in 6 children (more when a learning disability is also present), and is recommended by professional guidelines.
But it will not treat your child's autism — genetic testing answers “why” for some families. It does not change or improve autism itself; that was never the question it's built to answer.
When it finds something, it can genuinely help — about 72% of children with a positive result get at least one added medical recommendation (checking for related conditions, a specialist referral, avoiding an unsuitable treatment) — a real benefit for roughly 9–12% of everyone tested.
Most results come back negative or uncertain — an “uncertain” result (a genetic change whose meaning isn't known) is common, sometimes more common than a clear answer, and can cause worry without giving you one.
There are real information and insurance risks to know before testing — sequencing can reveal unrelated health findings, and federal law (GINA) does not protect life, disability, or long-term-care insurance. Coverage and access are uneven.
What this means for you
Genetic and metabolic testing looks at your child’s DNA — usually from a blood or saliva sample — to see whether a specific genetic change helps explain their autism. The most common tests are chromosomal microarray (CMA), Fragile X testing, and exome or genome sequencing. Autism itself is still diagnosed by watching how a child develops and behaves; the genetic test is not an autism test, and can’t be used to diagnose autism on its own. Testing finds a clear genetic cause in a minority of children — very roughly 1 in 10 with a microarray, closer to 1 in 6 with exome sequencing, and higher when a child also has a co-occurring intellectual disability. Fragile X testing turns up positive in about 1 in 100.
When testing does find a cause, it can be genuinely useful: among children who get a positive result, most families get at least one added recommendation from their doctor — checking for related conditions like seizures or heart issues, a referral to the right specialist, or steering away from a treatment that wouldn’t suit that child. A result can also tell you about the chance of the same condition in future children, and connect your family to others with the same diagnosis. What it will not do is treat the autism itself — that’s a different question genetic testing was never designed to answer. Most results, though, come back negative or uncertain: an “uncertain” result — a genetic change whose meaning isn’t yet known — is common, sometimes more common than a clear answer, and can cause real worry without giving your family anything to act on.
Before you test. Uncertain results are common, sequencing can reveal unrelated health information, and not every insurance type is protected from a genetic result being used against your family. It’s worth talking through what a positive, negative, or uncertain result would actually mean for you with a clinician or genetic counselor — ideally before testing, not after.
Where the studies landed
Established diagnostic toolEvery source here agrees that testing reliably finds what it looks for and that a positive result can genuinely change a family’s care. Where sources diverge is on access, uncertain results, and information risk — real and recurring, not disqualifying.
2 Points toward real diagnostic value
3 Real value, real friction
1 Highlights a real risk, not a benefit
Tap any tile to read it.
Points toward real diagnostic value2
Real value, real friction3
Highlights a real risk, not a benefit1
Spectrum Connect reviews published research on interventions parents are exploring for their autistic children — so you can see where the evidence actually stands. No agenda, no selling, no cherry-picking. Just the studies, our method, and what it means for you.
See the research behind this
For anyone who wants to check our work · 6 sources
Where we looked
This run was a scoping search only — done via general web search (2 searches: one for diagnostic yield and professional guidelines, one for clinical utility and VUS/secondary-findings/ELSI harms), not the reproducible Boolean search of record and not the PubMed/Epistemonikos API layer we use on a fully conformant run. That means we can’t publish reproducible per-database counts or a formal PRISMA flow for this run. Below is the search string a full conformant pass would run against PubMed, Embase, the Cochrane Library, Web of Science, and Epistemonikos, plus GeneReviews/ClinGen — we haven’t executed it against the database APIs yet.
(autism OR autistic OR ASD) AND ("chromosomal microarray" OR "fragile X" OR FMR1 OR "exome sequencing" OR "genome sequencing" OR "genetic testing" OR metabolic) AND ("diagnostic yield" OR "clinical utility" OR management OR "secondary findings")
Run on PubMed →
What we did with what we found
What the strongest evidence says
Finds a genetic cause in roughly 1 in 10 to 1 in 6 children tested (more with co-occurring intellectual disability). When positive, about 72% of families get at least one added medical recommendation.
Genetic testing is diagnostic, not therapeutic. It answers what’s causing your child’s autism for some families — it does not change or improve autism itself.
Uncertain results are common, sequencing can reveal unrelated health findings, and federal law (GINA) doesn’t cover life, disability, or long-term-care insurance.
Keep reading
What would you like to do?
Want to talk to a parent who’s been there?
We match you with families whose kid is like yours. Free, takes two minutes.
Heard of something we haven’t covered?Suggest an article
If another parent, a clinic or a video mentioned a therapy you can’t find here, tell us. We’ll read the research and review it next.
Suggest an articleThink we got something wrong?Report a factual error
We publish the whole record so it can be checked, and that only counts if we act on what you find. If a number looks wrong, a study is missing or has been retracted, or we’ve read a finding in a way the evidence doesn’t support, tell us.
You don’t need a research background to file one. “This doesn’t match what our doctor told us” is a useful report. Every one reaches a person: we reply within seven days, and within thirty we have either corrected the page or told you when we will. Substantive reports send the affected steps back through the protocol and need fresh sign-off before anything here changes.
Report a factual errorAre you a clinician or researcher?Review this article
If you have read this and the evidence holds up, you can sign off on it. We send you a personal review link where you confirm your credentials, and our team checks every review before anything is published. Once approved, your name and a link to your profile appear on this article.
Ask to review this